DENVER--(BUSINESS WIRE)--Medicine Man Technologies Inc. (OTCQX: MDCL) recently attended and presented at the Benzinga Cannabis Capital Conference in Miami Beach, Florida. On day two of the conference, Justin Dye, Chief Executive Officer, presented to a full room of conference attendees an update of the growth strategy and how the Company is progressing on the closings of the pending acquisitions.
Medicine Man Technologies is a rapidly growing provider of cannabis consulting services, nutrients, and supplies. In response to the legislative change with Colorado House Bill 19-1090, the Company entered into agreements with 11 premier cannabis operators across the state of Colorado to become one of the largest vertically integrated seed-to-sale operators in the global cannabis industry. Once complete, these agreements will enable Medicine Man Technologies to offer:
- cultivation capabilities at 13 indoor, greenhouse and outdoor facilities totaling 2.1M growing square feet,
- extraction and production capabilities at five facilities totaling 23,000 manufacturing square feet,
- 34 dispensary operations totaling 64,000 retail square feet, and
- product development and innovation.
“For the past couple of months, we have had our heads down focused on building a strong, agile infrastructure to support our growth initiatives. As such, we have been intentionally quiet during this time and decided Benzinga Cannabis Capital Conference would be a good time to share where we are as a company,” said Justin Dye, Chief Executive Officer. “I am pleased to report that we are on a solid path and scheduled to become the largest cannabis operator in the great state of Colorado. Since joining the Company as CEO in December, we have been laser focused on finalizing diligence and integration planning with our acquisition partners, deploying our company operating playbook and implementing our new enterprise ERP platform. We are building a company that is based on fundamentals, operating excellence, and driving sustainable EBITDA, which never goes out of style. I am energized by not only our progress but also by the team’s high-level and thoughtful execution, which is the expectation. We are grateful for the opportunity to make a positive difference in people’s lives and continue to be excited about our future.”
To learn more about the company and where it is heading, please view the new Investor Presentation on the Company’s website https://ir.MedicineManTechnologies.com/. For more information about Medicine Man Technologies, please visit https://www.MedicineManTechnologies.com/.
About Medicine Man Technologies
Denver, Colorado-based Medicine Man Technologies (OTCQX: MDCL) is a rapidly growing provider of cannabis consulting services, nutrients, and supplies. The Company's client portfolio includes active and past clients throughout the cannabis industry in 20 states and seven countries. The Company has entered into agreements to become one of the largest vertically integrated seed-to-sale operators in the global cannabis industry. Current agreements will enable Medicine Man Technologies to offer cultivation, extraction, distribution and retail pharma-grade products. Management includes decades of cannabis experience, a unique combination of first movers in industrial cannabis and proven Fortune 500 corporate executives.
Forward-Looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified. Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.